Sweet and Sour

(Feb 17, 2016)

Public health initiatives, such as those being considered in the UK around sugar, carry risks as well as potential benefits for any government. The first consequence of action is the near-certain accusation of presiding over a nanny state. Although the archetypal nanny, Mary Poppins, was famously enamoured with sugar's ability to help the medicine go down, nowadays, most debate is around whether it actually sends our societal need for medicine in the opposite direction. Is sugar a particular driver of mortality and morbidity that merits state intervention? The World Health Organisation seems to think so, with it's recent report on Ending Childhood Obesity making an unequivocal call for effective taxes…

Read more

Tags: longevity, sugar tax, obesity, diabetes, health intervention

Old Drugs, New Tricks

(Jan 8, 2016)

Breakthrough science in the longevity space doesn't always require the development of new medicines. In fact, there are significant advantages to repurposing medicines already in use, since some of the most expensive aspects of drug development lie in establishing human safety in the trial phase. Drugs already in use have a safety profile and a significant body of existing research to draw upon; further trials need focus mainly upon demonstrating efficacy against the new condition. This not only lowers costs for any sponsoring pharmaceutical company, but should deliver effective treatments to patients on a much shorter timescale.

One recent example is the asthma drug, montelukast, which is attracting…

Read more

Tags: longevity, research, regenerative medicine, cognitive impairment, diabetes

Find by key-word

Find by date

Find by tag (show all )